BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND MLLT1, ENL, 4298, ENSG00000130382, Q03111, YEATS1, LTG19
230 results:

  • 1. Structural studies of intrinsically disordered MLL-fusion protein AF9 in complex with peptidomimetic inhibitors.
    Yang Y; Ahmad E; Premkumar V; Liu A; Ashikur Rahman SM; Nikolovska-Coleska Z
    Protein Sci; 2024 Jun; 33(6):e5019. PubMed ID: 38747396
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. A complex interplay of intra- and extracellular factors regulates the outcome of fetal- and adult-derived MLL-rearranged leukemia.
    Jassinskaja M; Ghosh S; Watral J; Davoudi M; Claesson Stern M; Daher U; Eldeeb M; Zhang Q; Bryder D; Hansson J
    Leukemia; 2024 May; 38(5):1115-1130. PubMed ID: 38555405
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Bahcc1 is critical for the aberrant epigenetic program in a mouse model of MLL-enl-mediated leukemia.
    Nakamura A; Masuya M; Shinmei M; Tawara I; Nosaka T; Ono R
    Blood Adv; 2024 May; 8(9):2193-2206. PubMed ID: 38452334
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Targeting the Epigenetic Reader enl Inhibits Super-Enhancer-Driven Oncogenic Transcription and Synergizes with BET Inhibition to Suppress Tumor Progression.
    Chen Y; Ying Y; Ma W; Ma H; Shi L; Gao X; Jia M; Li M; Song X; Kong W; Chen W; Zheng X; Muluh TA; Wang X; Wang M; Shu XS
    Cancer Res; 2024 Apr; 84(8):1237-1251. PubMed ID: 38241700
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. IKZF3 polymorphisms contribute to the increased risk of acute lymphoblastic leukemia in children.
    Yang X; Yang L; Luo A; Liu S; Zhang X; Liu X; Liu X; Luo A; Cai M; Yan Y; Wu X; Huang K; Xu L; Jiang H
    Cancer; 2024 Mar; 130(6):973-984. PubMed ID: 38018448
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Droplet Digital PCR for Oncogenic KMT2A Fusion Detection.
    Young AL; Davis HC; Challen GA
    J Mol Diagn; 2023 Dec; 25(12):898-906. PubMed ID: 37813299
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. AFF4 globally affects the release of paused RNA polymerase II in HEL cells.
    Yang ZM; Zhang G; Wei G; Jing LL; Yu M
    Yi Chuan; 2023 Aug; 45(8):658-668. PubMed ID: 37609817
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The YEATS domain epigenetic reader proteins enl and AF9 and their therapeutic value in leukemia.
    Hu H; Muntean AG
    Exp Hematol; 2023 Aug; 124():15-21. PubMed ID: 37295550
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Anti-MDA5 antibody-positive rapidly progressive interstitial lung disease after allogeneic hematopoietic cell transplantation successfully treated with triple immunosuppressive therapy].
    Nakamura Y; Kawamura S; Matsumi S; Matsumoto K; Tanaka S; Ishikawa T; Matsuoka A; Meno T; Kawamura M; Takeshita J; Yoshino N; Yoshimura K; Misaki Y; Gomyo A; Okada Y; Tamaki M; Kusuda M; Akahoshi Y; Kameda K; Wada H; Kimura SI; Nakasone H; Kako S; Date H; Kanda Y
    Rinsho Ketsueki; 2023; 64(4):250-254. PubMed ID: 37121767
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. MOZ/enl complex is a recruiting factor of leukemic AF10 fusion proteins.
    Komata Y; Kanai A; Maeda T; Inaba T; Yokoyama A
    Nat Commun; 2023 Apr; 14(1):1979. PubMed ID: 37031220
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Conformational and Thermodynamic Differences Underlying Wild-Type and Mutant Eleven-Nineteen-leukemia YEATS Domain Specificity for Epigenetic Marks.
    Baweja L; Wereszczynski J
    J Chem Inf Model; 2023 Feb; 63(4):1229-1238. PubMed ID: 36786550
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. A fetal tumor suppressor axis abrogates MLL-fusion-driven acute myeloid leukemia.
    Eldeeb M; Yuan O; Guzzi N; Thi Ngoc PC; Konturek-Ciesla A; Kristiansen TA; Muthukumar S; Magee J; Bellodi C; Yuan J; Bryder D
    Cell Rep; 2023 Feb; 42(2):112099. PubMed ID: 36763502
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Design, synthesis of novel benzimidazole derivatives as enl inhibitors suppressing leukemia cells viability via downregulating the expression of MYC.
    Guo S; Jia T; Xu X; Yang F; Xiao S; Hou Z; Xu H; Ma S; Liu X; Luo C; Jiang H; Chen H; Chen S
    Eur J Med Chem; 2023 Feb; 248():115093. PubMed ID: 36645983
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Prognostic value and outcome for acute lymphocytic leukemia in children with MLL rearrangement: a case-control study.
    Qiu KY; Zhou DH; Liao XY; Huang K; Li Y; Xu HG; Weng WJ; Xu LH; Fang JP
    BMC Cancer; 2022 Dec; 22(1):1257. PubMed ID: 36461002
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. EVI1 exerts distinct roles in AML via ERG and cyclin D1 promoting a chemoresistant and immune-suppressive environment.
    Masamoto Y; Chiba A; Mizuno H; Hino T; Hayashida H; Sato T; Bando M; Shirahige K; Kurokawa M
    Blood Adv; 2023 Apr; 7(8):1577-1593. PubMed ID: 36269819
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Small-Molecule Inhibition of the Acyl-Lysine Reader enl as a Strategy against Acute Myeloid leukemia.
    Liu Y; Li Q; Alikarami F; Barrett DR; Mahdavi L; Li H; Tang S; Khan TA; Michino M; Hill C; Song L; Yang L; Li Y; Pokharel SP; Stamford AW; Liverton N; Renzetti LM; Taylor S; Watt GF; Ladduwahetty T; Kargman S; Meinke PT; Foley MA; Shi J; Li H; Carroll M; Chen CW; Gardini A; Maillard I; Huggins DJ; Bernt KM; Wan L
    Cancer Discov; 2022 Nov; 12(11):2684-2709. PubMed ID: 36053276
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Multi-omics analysis defines highly refractory RAS burdened immature subgroup of infant acute lymphoblastic leukemia.
    Isobe T; Takagi M; Sato-Otsubo A; Nishimura A; Nagae G; Yamagishi C; Tamura M; Tanaka Y; Asada S; Takeda R; Tsuchiya A; Wang X; Yoshida K; Nannya Y; Ueno H; Akazawa R; Kato I; Mikami T; Watanabe K; Sekiguchi M; Seki M; Kimura S; Hiwatari M; Kato M; Fukuda S; Tatsuno K; Tsutsumi S; Kanai A; Inaba T; Shiozawa Y; Shiraishi Y; Chiba K; Tanaka H; Kotecha RS; Cruickshank MN; Ishikawa F; Morio T; Eguchi M; Deguchi T; Kiyokawa N; Arakawa Y; Koh K; Aoki Y; Ishihara T; Tomizawa D; Miyamura T; Ishii E; Mizutani S; Wilson NK; Göttgens B; Miyano S; Kitamura T; Goyama S; Yokoyama A; Aburatani H; Ogawa S; Takita J
    Nat Commun; 2022 Aug; 13(1):4501. PubMed ID: 36042201
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Poor treatment responses were related to poor outcomes in pediatric B cell acute lymphoblastic leukemia with KMT2A rearrangements.
    Wen J; Zhou M; Shen Y; Long Y; Guo Y; Song L; Xiao J
    BMC Cancer; 2022 Aug; 22(1):859. PubMed ID: 35933338
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Design, Synthesis, and Biological Evaluations of DOT1L Peptide Mimetics Targeting the Protein-Protein Interactions between DOT1L and MLL-AF9/MLL-enl.
    Yuan Y; Du L; Tan R; Yu Y; Jiang J; Yao A; Luo J; Tang R; Xiao Y; Sun H
    J Med Chem; 2022 Jun; 65(11):7770-7785. PubMed ID: 35612819
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. A somatic mutation in moesin drives progression into acute myeloid leukemia.
    Yuan O; Ugale A; de Marchi T; Anthonydhason V; Konturek-Ciesla A; Wan H; Eldeeb M; Drabe C; Jassinskaja M; Hansson J; Hidalgo I; Velasco-Hernandez T; Cammenga J; Magee JA; Niméus E; Bryder D
    Sci Adv; 2022 Apr; 8(16):eabm9987. PubMed ID: 35442741
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 12.